When EC REP Is Still Acceptable on a Medical Device Label After 17 June 2026: ISO 15223-1:2021/Amd 1:2025 XX REP and EU REP, Commission Implementing Decisions (EU) 2026/1231 and 2026/1313, MDCG 2021-5 Rev. 1 Appendix, FDA Recognition 5-148 versus 5-134, 21 CFR 801.15, and Why a Notified Body Does Not Have to Pre-Approve the Editorial Change

This technical guide is written for international medical-device distributors, contract manufacturing (OEM/ODM) buyers, hospital incoming-inspection teams, and regulatory affairs personnel evaluating Chinese-manufactured sterile single-use devices under European Union and United States labeling frameworks. It provides actionable criteria to distinguish compliant coexistence artwork from genuine nonconformities, preventing unwarranted shipment rejections, commercial disputes, and unnecessary re-labeling expenditures.

Table of contents

1. Does a CE-marked pouch that still prints EC REP become nonconforming on 17 June 2026, or only when the old EN ISO 15223-1:2021 OJEU entry is withdrawn?
2. What did ISO 15223-1:2021/Amd 1:2025 actually change: definition 3.20, generic XX REP, and EU REP as the Union example?
3. Why are the MDR and IVDR withdrawal dates different: 15 June 2031 in Decision 2026/1231 versus 17 June 2031 in Decision 2026/1313?
4. Does a notified body have to pre-approve the EC REP to EU REP artwork change?
5. Can EC REP and EU REP appear on different packaging levels, and when is over-labelling acceptable?
6. What happens to stock already placed on the Union market with EC REP after the 2031 date?
7. Does FDA recognition 5-148 / 5-134 or 21 CFR 801.15 copy the EU 2031 clock onto a US-bound label?
8. Is EU REP the same legal role as an EU importer, a UK Responsible Person, or a Swiss CH-REP?
9. Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber, and why NOVACURE's CE flag is out of scope
10. Distributor incoming-label checklist, red flags, and the pack to request before accepting the lot
11. Where VEMERIX fits—and where due diligence still begins
12. Frequently asked questions

Does a CE-marked pouch that still prints EC REP become nonconforming on 17 June 2026, or only when the old EN ISO 15223-1:2021 OJEU entry is withdrawn?

When a European distributor or hospital receiving dock inspects a sterile single-use device pouch, few visual elements prompt faster questions than an apparent labelling discrepancy. In mid-2026, regulatory-consultancy pages framed the Official Journal citation of Amendment 1 to EN ISO 15223-1 as an urgent artwork crisis—one widely cited headline called it “the symbol shift you can’t ignore”. Incoming-inspection teams were left asking whether a CE-marked sterile single-use lot that still prints the classic EC REP symbol beside a named European authorised representative must be rejected, over-labelled, or held for a notified-body letter.

This panic is legally and procedurally unfounded. A sterile single-use pouch or secondary carton that still prints the ISO 15223-1 Clause 5.1.2 EC REP symbol did not become nonconforming on 17 June 2026, nor does it face immediate border impoundment or regulatory recall ³. To understand why, one must examine the statutory mechanics of European Union harmonised standards under Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR) ⁶, ¹⁵.

Under MDR Article 8(1) and IVDR Article 8(1), devices that conform to harmonised standards cited in the Official Journal of the European Union (OJEU) enjoy a formal presumption of conformity with the requirements covered by those standards. Annex I, Section 23.1(h) of the MDR and Section 20.1(h) of the IVDR state that, where appropriate, the information supplied by the manufacturer shall take the form of internationally recognised symbols, and that any symbol or identification colour used shall conform to the harmonised standards or common specifications ⁶, ¹⁵. On 17 June 2026, the European Commission published Commission Implementing Decision (EU) 2026/1231 (for MDR) ⁴ and Commission Implementing Decision (EU) 2026/1313 (for IVDR) ⁵. These decisions officially cited EN ISO 15223-1:2021/A1:2025 in the Official Journal.

Crucially, the legal act that introduces an amended harmonised standard does not instantly extinguish the legal validity of the preceding standard. Instead, European standardisation law relies on a staggered transition mechanism established in the Annex and operative Articles of the Implementing Decisions. Article 2 of Commission Implementing Decision (EU) 2026/1231 specifies that Point (5) of its Annex—which formally deletes entry No 12 (the unamended EN ISO 15223-1:2021)—shall apply from 15 June 2031 ⁴. Similarly, Article 2 of Commission Implementing Decision (EU) 2026/1313 specifies that Point (1) of its Annex—which deletes entry No 8 for the IVDR—shall apply from 17 June 2031 ⁵.

Consequently, between 17 June 2026 and June 2031, a full 60-month coexistence window exists under European law. During this five-year transitional period, both the unamended standard (authorizing EC REP) and the amended standard (authorizing EU REP) remain concurrently cited in the Official Journal. Both symbols confer an identical, uncompromised presumption of conformity with MDR Annex I Section 23.1(h) and IVDR Annex I Section 20.1(h) ³. Rejecting an incoming shipment of sterile single-use devices in 2026 solely because its pouch artwork displays EC REP is a critical QA misinterpretation that conflates the publication of an amendment with the formal withdrawal of the prior standard.

What did ISO 15223-1:2021/Amd 1:2025 actually change: definition 3.20, generic XX REP, and EU REP as the Union example?

To assess artwork accurately, technical and quality teams must understand the precise technical changes introduced by ISO 15223-1:2021/Amd 1:2025 (standard entry 86270, amending parent standard 77326) ¹, ². The amendment was not conceived as a clinical, biological, or physical modification to medical devices. Rather, its origin lies in Commission Decision C(2024)3371 (standardisation request M/575 Amendment 2), as cited by MDCG ¹¹. The Commission requested CEN and CENELEC to revise EN ISO 15223-1 to remove obsolete terminology referencing the 'European Community' (EC), an entity that legally ceased to exist following the entry into force of the Treaty of Lisbon on 1 December 2009.

When ISO/TC 210 addressed this request at the international level, it did more than swap two letters:

• Addition of defined term 3.20: Amendment 1 adds a definition of “authorized representative” generally referred to a country or jurisdiction (clause 3.20), rather than only to the European Community ¹, ³. The paywalled ISO clause body is not reproduced here; the public legal narrative is the MDCG paraphrase.
• Clause 5.1.2 becomes generic XX REP: In EN ISO 15223-1:2021, clause 5.1.2 presented the symbol EC REP for “Authorized representative in the European Community/European Union”. Amendment 1 introduces in clause 5.1.2 the generic symbol XX REP for the authorised representative in the identified country or jurisdiction ¹, ³.
• The Mechanics of Generic XX REP: Under the amended standard, XX serves as a variable placeholder to be replaced by the ISO 3166-1 two- or three-letter country/region code, or other specific text required by the relevant national competent authority. For the European Union, the standard explicitly provides EU REP as the normative example for an authorised representative established in the Union ³.

A widespread misconception in commercial commentary is that the XX REP framework automatically authorizes manufacturers to invent arbitrary national symbols for every export destination. In a news release on 17 August 2026 discussing the update, CEN-CENELEC illustrated the generic nature of XX REP by referencing hypothetical constructs such as UK REP for the United Kingdom or CH REP for Switzerland ¹⁰. Quality managers must recognize that CEN-CENELEC's illustrative examples are not MHRA law and not Swissmedic law. A GB placing-on-the-market file still follows the UK Medical Devices Regulations 2002 as applied by MHRA; a Swiss file still follows MedDO. National labelling law controls over a standards-body example.

Why are the MDR and IVDR withdrawal dates different: 15 June 2031 in Decision 2026/1231 versus 17 June 2031 in Decision 2026/1313?

When evaluating supplier compliance dossiers and Declarations of Conformity (DoCs), technical auditors frequently notice a two-day discrepancy between the withdrawal dates cited for the medical device regulation and the in vitro diagnostic regulation. Industry trade summaries almost universally flatten these dates into a generic phrase: 'a five-year transition until June 2031' or 'labels must change by 17 June 2031'. In a rigorous regulatory audit, precision matters. The two-day difference is neither a typographical error nor an editorial oversight; it is the binding statutory text enacted in the Official Journal ⁴, ⁵.

In Commission Implementing Decision (EU) 2026/1231, adopted on 11 June 2026 and published on 17 June 2026, Recital 12 provides the explicit policy rationale for granting a five-year coexistence window for EN ISO 15223-1:2021. The Commission recorded that sectoral interested parties in the MDCG Subgroup on Standards had shown a significant impact on economic operators in costs and timing to implement labelling changes in manufacturing and distribution, at both EU and international level. An abrupt transition would not, on that record, be proportionate to a purely editorial terminology update ⁴.

To give effect to this policy, Article 2 of Decision (EU) 2026/1231 sets the withdrawal date: 'Point (5) of the Annex shall apply from 15 June 2031'. Point (5) formally deletes entry No 12 of Implementing Decision (EU) 2021/1182 (the unamended EN ISO 15223-1:2021), while Point (6) inserts entry No 12a (the amended standard EN ISO 15223-1:2021/A1:2025) ⁴.

By contrast, Commission Implementing Decision (EU) 2026/1313 for in vitro diagnostics was adopted on 15 June 2026 and published on 17 June 2026. Article 2 of Decision (EU) 2026/1313 stipulates: 'Point (1) of the Annex shall apply from 17 June 2031'. Point (1) deletes entry No 8 of Implementing Decision (EU) 2021/1195 (the unamended IVD standard entry), while Point (2) inserts entry No 8a ⁵. MDCG 2021-5 Rev. 1 Appendix describes a 60-month coexistence window running to 17 June 2031. The MDR Decision’s Article 2 cell is one day earlier. Both dates are binding for their respective regulations; a buyer matrix should print both rather than flatten them into a single “June 2031” slogan ³, ⁴, ⁵.

The table below establishes the official transition and withdrawal clocks across European and United States regulatory instruments, contrasting binding statutory dates against common consultancy slogans.

The transition period duration across these major regulatory mechanisms can also be visualized in terms of operational runway from the June 2026 European publication date:

Does a notified body have to pre-approve the EC REP to EU REP artwork change?

A primary driver of supply-chain friction in mid-2026 was search-summary and consultancy language telling manufacturers they cannot adopt EU REP without prior notified-body review, or that they should wait to proceed “as advised by their Notified Body”. That advice is not the MDCG file. It can send incoming inspection looking for a notified-body approval letter or certificate supplement the appendix says is not required.

The official European regulatory position directly contradicts this assertion. In June 2026, the Medical Device Coordination Group issued MDCG 2021-5 Rev. 1 Appendix, titled 'Guidance on standardisation for medical devices — Appendix: Transition to the “EU REP” symbol in EN ISO 15223-1' ³. On the notified-body question the appendix is direct:

• Purely editorial nature: MDCG states that the change from EC REP to EU REP is purely editorial. It reflects a terminology update only ³.
• No impact on safety or performance: The change has no impact on the health, safety and performance characteristics of the device, nor on the role, responsibilities, location or legal obligations of the authorised representative ³.
• No Alteration of the Legal Mandate: The change does not alter the legal appointment, identity, registered address, or statutory obligations of the sole authorised representative established under MDR Article 11 or IVDR Article 11. The natural or legal person acting as the authorised representative remains unchanged because the letters changed ³, ⁶, ¹⁵.
• No prior notified-body approval: MDCG states that the manufacturer does not need prior approval from a notified body (if its involvement is required) for that labelling change. Distributors should not treat a search-summary “wait for your notified body” instruction as a certificate-supplement gate ³.

MDCG does not require a prior notified-body approval letter, certificate supplement or standalone permission for this editorial labelling change. A distributor who halts a CE-marked lot solely to wait for that letter is applying a gate the appendix does not set. Surveillance of the symbols standard remains a later notified-body file, not an incoming-lot hold. For detailed criteria on how to verify legitimate CE certificates without fabricating false approval requirements, see our guide on how to verify the CE certificate that may support the label without treating notified-body approval as required for EC REP to EU REP.

Can EC REP and EU REP appear on different packaging levels, and when is over-labelling acceptable?

In modern sterile device manufacturing, packaging is multi-tiered. A typical sterile consumable involves at least three distinct packaging levels: the primary sterile barrier (for example a peelable pouch or blister pack), the secondary protective packaging (a printed unit folding box or shelf carton), and the tertiary transit packaging (a corrugated shipping carton holding multiple shelf boxes), accompanied by printed Instructions for Use (IFU). Quality control inspectors frequently encounter lots where the primary pouch displays EC REP, while the secondary folding carton or IFU displays EU REP, or vice versa. The immediate question is whether this mixed presentation constitutes a packaging nonconformity.

MDCG 2021-5 Rev. 1 Appendix explicitly authorizes this mixed packaging structure during the 60-month coexistence period ³. Recognizing that manufacturers maintain differing inventory turn rates for pre-printed foil pouches, outer boxes, and instruction booklets, the guidance provides:

During the transition time, within a staggered approach for the implementation, it is acceptable to use one or both symbols ‘EC REP’ and ‘EU REP’ on different levels of packaging, as well as re-labelling/over-labelling solutions, provided that the information on the authorised representative remains clear and intelligible.— MDCG 2021-5 Rev. 1 Appendix (June 2026)

The mandatory compliance condition is that the substantive information—the authorised representative's legal name, trade name, and full physical address—must be completely identical across every tier of packaging. What is prohibited is an ambiguous presentation where the primary pouch names 'Consultant A' as the EC REP while the outer carton names 'Consultant B' as the EU REP, implying two different entities or an uncoordinated mandate transition ³.

Furthermore, MDCG 2021-5 Rev. 1 Appendix addresses re-labeling and over-labeling. If a manufacturer or economic operator chooses to apply an over-label (adhesive sticker) to update EC REP to EU REP, the practice is legally acceptable under the following strict conditions:

• Do not obscure mandatory identifiers: MDCG’s test is that authorised-representative information remains clear and intelligible. Separately, MDR labelling rules still require UDI, lot, and expiry data to remain readable. An over-label that hides the UDI carrier or lot number fails that broader file even if the letters now read EU REP ³, ⁶. For UDI assignment versus adjacent artwork, see why a UDI barcode is not a substitute for the authorised-representative symbol.
• Sterile-barrier integrity is a separate test: Over-labels applied to a primary sterile barrier must not be assumed safe merely because the letters changed. Adhesive, substrate and sterilisation-cycle validation remain the manufacturer’s process file; they are not specified in the MDCG appendix.
• Manufacturer versus downstream operator: Manufacturer-controlled reprints or manufacturer-applied over-labels sit on the editorial MDCG path. If an importer or distributor, rather than the legal manufacturer, changes labels or outer packaging in the Union, MDR Article 16 may apply; that is a different operator test from the letters EC versus EU and is not rebuilt here. See who is the legal manufacturer whose EU authorised representative must appear beside EU REP or EC REP ⁶.

What happens to stock already placed on the Union market with EC REP after the 2031 date?

A major concern for hospital procurement directors and long-term device stockists is what will occur when the clock expires on 15 June 2031 (MDR) or 17 June 2031 (IVDR). Specifically: must distributors scrap remaining warehouse inventory that still displays EC REP? Must hospitals return unopened sterile kits to the manufacturer?

The answer is unequivocally no. The governing principle of European product law is the fundamental legal distinction between 'placing on the market' and 'making available on the market'. Under MDR Article 2(28), 'placing on the market' means the first making available of a device, other than an investigational device, on the Union market. Under Article 2(27), 'making available on the market' means any supply of a device, other than an investigational device, for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge ⁶.

MDCG 2021-5 Rev. 1 Appendix explicitly cites Section 4.1.2.5 of the European Commission's 'Blue Guide' on the implementation of EU product rules 2022 (OJ C 247, 29.6.2022, p. 1) ³, ¹². The Blue Guide’s revision-of-standards section, as applied by MDCG here, is that a purely editorial change which does not concern health, safety or performance does not force devices already lawfully placed on the Union market off that market. MDCG states those devices may continue to be made available ³, ¹².

Therefore, any sterile consumable manufactured, packaged with EC REP, and transferred from the non-EU legal manufacturer to a European importer or distributor before the mid-June 2031 deadline remains fully marketable. There is no statutory basis for mandatory recalls, no requirement for retrospective over-labeling in field inventory, and no justification for hospital receiving departments to reject stock that was lawfully placed on the market prior to the withdrawal date.

Does FDA recognition 5-148 / 5-134 or 21 CFR 801.15 copy the EU 2031 clock onto a US-bound label?

When Chinese sterile medical device manufacturers operate global production facilities, packaging engineering teams often attempt to standardize packaging across multiple export jurisdictions. A common error among international distributors is assuming that the European Union's 2031 transition clock automatically governs devices destined for the United States, or conversely, that US FDA consensus standard transitions apply in Europe. In reality, the United States Food and Drug Administration (FDA) operates an independent statutory and administrative framework.

An independent recompute of the FDA Recognized Consensus Standards snapshot dated 26 August 2026 (1,898 directory rows, including standards still listed during a transition) found exactly two ISO 15223-1 recognition rows. That row count is a directory fact, not a count of labelled devices and not a ‘current-only’ census of live FDA recognitions ⁸:

• Recognition Number 5-148: Listed under FR Recognition List Number 065 with Date of Entry 22 December 2025. This entry grants complete recognition to 'ISO 15223-1 Fourth edition 2021-07 [Including AMD1: 2025] Medical devices — Symbols to be used with information to be supplied by the manufacturer — Part 1: General requirements'. The Transition Expiration Date field is empty, indicating that it is the current, active baseline recognition standard ⁷, ⁸.
• Recognition Number 5-134: Listed in the 26 August 2026 directory snapshot with date of entry 20 December 2021 (FR Recognition List Number 058 in that snapshot). This entry covers the unamended Fourth edition. The live Rec# 5-148 SIS is the public source for the explicit Transition Expiration Date of 17 December 2028 ⁷, ⁸.

What does this mean in practical regulatory terms? In the United States, FDA recognition of consensus standards under Section 514(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) facilitates premarket clearance. In 510(k) notifications, De Novo classifications, and Premarket Approval (PMA) applications, an applicant may submit a Declaration of Conformity (DoC) to a recognized standard in lieu of submitting voluminous raw test data. The FDA SIS for Rec# 5-148 states explicitly that FDA will continue to accept Declarations of Conformity to Rec# 5-134 in support of premarket submissions until 17 December 2028 ⁷. After that date, any new premarket submission referencing ISO 15223-1 must declare conformity to Rec# 5-148 (including Amendment 1:2025).

This 17 December 2028 deadline is an FDA premarket submission acceptance cutoff, not an in-market labeling withdrawal deadline. Furthermore, it operates on a timeline that expires 2.5 years earlier than the European Union's 2031 withdrawal dates. Conflating the FDA 2028 transition with the EU 2031 transition creates profound regulatory confusion.

Even more critical is the substantive labeling requirement under 21 CFR Part 801.15 (Medical devices; prominence of required label statements; use of symbols in labeling) ⁹. Under 21 CFR 801.15(c)(1), medical device labeling must be in the English language. A manufacturer may use a symbol from an FDA-recognized standard (such as ISO 15223-1) without adjacent explanatory English text only if two strict conditions are satisfied:

• Recognition and Standard Alignment: The symbol must be used in accordance with the specifications in the FDA recognition (such as Rec# 5-148 or 5-134) or determined by the manufacturer to meet the standard criteria under 801.15(c)(1)(i)(E) ⁹.
• Mandatory Symbols Glossary: The labeling must bear, or be accompanied by, a prominent Symbols Glossary that defines each standalone symbol used on the device or its packaging. The glossary must be clearly identified on the labeling (e.g. in the package insert or IFU) ⁹.

The vital takeaway for US-bound shipments: US FDA law does not require an authorised representative symbol on medical devices. An authorized representative is a creature of European (and certain other international) regulatory systems; the United States requires the name and place of business of the manufacturer, packer, or distributor under 21 CFR 801.1, alongside an FDA U.S. Agent designated in the establishment registration under 21 CFR Part 807. If a manufacturer uses standardized global packaging that prints EC REP or EU REP on a pouch shipped to the US, the symbol is legally superfluous export data. However, if the pouch uses standalone symbols (such as sterile barrier, EO, use-by date, or manufacturer symbols) without English text, the shipment will be deemed misbranded under Section 502(c) of the FD&C Act unless accompanied by a compliant 21 CFR 801.15 Symbols Glossary ⁹. For broader inspection requirements, see why a US 820.45 labeling-inspection file is not the EU EC REP / EU REP clock.

Is EU REP the same legal role as an EU importer, a UK Responsible Person, or a Swiss CH-REP?

When auditing international device packaging, quality teams often discover that procurement personnel blend distinct statutory roles into a single generic bucket labeled 'the overseas representative'. An incoming package that prints EU REP does not automatically satisfy European importer obligations, does not satisfy post-Brexit Great Britain market placement rules, and does not permit commercial sale in Switzerland. Each entity is governed by a separate legal instrument, holds distinct liabilities, and requires unique labeling representations.

The distinctions among these key economic operators and jurisdictional representatives are structured below:

• EU Authorised Representative (EU REP / EC REP): Governed strictly by MDR Article 11 and IVDR Article 11 ⁶. When a manufacturer is not established in an EU Member State, it must appoint a sole authorised representative in the Union under a formal written mandate. The authorised representative serves as the legal interlocutor between the non-EU manufacturer and European competent authorities, maintains an up-to-date copy of the technical documentation, verifies the Declaration of Conformity and conformity assessment, cooperates on vigilance reporting, and terminates the mandate if the manufacturer acts contrary to MDR obligations. The symbol used under ISO 15223-1 Clause 5.1.2 is EC REP (valid to 2031) or EU REP ³.
• EU Importer: Governed by MDR Article 13 and IVDR Article 13 ⁶. The importer is the natural or legal person established within the Union who places a device from a third country on the Union market. The importer has an independent legal obligation to verify that the device is CE-marked, an EU Declaration of Conformity is drawn up, an authorised representative is designated by the manufacturer, and the device is labeled in accordance with the regulation. Crucially, under MDR Article 13(3), importers must indicate on the device or its packaging (or in a document accompanying the device) their name, registered trade name, and address. In ISO 15223-1, the importer is identified by the clause 5.1.8 importer symbol or explicit importer text, not by the EU REP symbol. This page does not reproduce ISO artwork. An authorised representative cannot act as an importer unless it actually performs the physical commercial placing on the market and assumes Article 13 liabilities.
• UK Responsible Person (UKRP): Governed by the UK Medical Devices Regulations 2002 (SI 2002 No 618 as amended) for goods placed on the market in Great Britain (England, Scotland, and Wales). Under current UK MHRA transitional policy, CE-marked medical devices continue to be recognized for placing on the GB market. For CE-route devices, the packaging requires the manufacturer's details and its designated European authorised representative (which may still appear as EC REP or EU REP); UKRP details are required only where devices are UKCA-marked or dual-marked. CEN-CENELEC informational materials reference UK REP as a conceptual XX REP example ¹⁰; that example is not the MHRA GB instrument. Distributors should review our dedicated analysis on why a UK Responsible Person is not the EU REP symbol, and when a CE-route GB label may still show EC REP.
• Swiss Authorised Representative (CH-REP): Governed by the Swiss Medical Devices Ordinance (MedDO, SR 812.213) and In Vitro Diagnostic Devices Ordinance (IvDO, SR 812.219). Following the collapse of the EU-Swiss Institutional Framework Agreement and the cessation of mutual recognition in May 2021, foreign manufacturers (including EU manufacturers) placing devices on the Swiss market must appoint a CH-REP established in Switzerland. Swissmedic requires the CH-REP name and address to appear on the label or accompanying documentation. An EU REP symbol alone does not provide lawful representation in Switzerland. The CEN-CENELEC CH REP example is not that Swissmedic file.
• EUDAMED Single Registration Number (SRN): Issued by national competent authorities under MDR Article 31 following actor registration. An SRN identifies the economic operator (manufacturer, AR, importer) in the European database, but printing an SRN is an administrative identification, not a substitute for the Clause 5.1.2 physical packaging symbol.

The comparative matrix below outlines the core attributes, statutory authorities, and packaging requirements across these distinct roles:

Distributors must verify that their agreements reflect the proper legal status. For guidance on contract manufacturing structures, review who is the legal manufacturer whose EU authorised representative must appear beside EU REP or EC REP.

Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber, and why NOVACURE's CE flag is out of scope

To anchor these technical principles in real-world supply chain management, consider two contrasting surgical device product lines manufactured by Weihai Medison Medical Equipment Co., Ltd. and commercialized under the international brand VEMERIX. These examples demonstrate when the EC REP symbol is fully compliant and when an authorized representative symbol must never appear on packaging.

Worked example 1: the CE-marked circumcision device (positive coexistence case)

The VEMERIX Circumcision Device is an ethylene oxide (EO) sterilized, single-use self-detaching surgical ring. The public product page records NMPA Class II registration Lu Mech Reg. 20172020238, individual sterile blister packaging, and a CE mark ¹³. That page is identity for the CE-route worked example; it is not a screenshot of current clause 5.1.2 artwork, an SRN, or an EU class. For context on the broader evidence dossier, see the circumcision registration evidence pack that still names ISO 15223-1:2021 without the 2025 amendment.

The incoming decision: If this CE-marked SKU arrives in 2026 with EC REP still printed beside a named Union authorised representative whose name and address match a written MDR Article 11 mandate, an international distributor or hospital QA inspector can accept the lot on the symbol clock. Under Commission Implementing Decision (EU) 2026/1231, EC REP still enjoys a statutory presumption of conformity until 15 June 2031 ⁴. Under MDCG 2021-5 Rev. 1 Appendix, the manufacturer does not need prior notified-body approval to update later reprints to EU REP ³. Demanding an emergency artwork re-print, or issuing a nonconformance solely for the letters EC, is not the official test. The buyer should still request the current artwork, the mandate, and the Declaration of Conformity rather than infer those files from the product page.

Worked Example 2: The Disposable Medical Laser Fiber (Negative Worked Example):

The VEMERIX Disposable Medical Laser Fiber is an NMPA Class II registered single-use sterile device (Lu Mech Reg. 20192010517) described for 1470 nm endovenous laser workflows. The public product page records that NMPA identity and does not record a Medison CE mark for this SKU ¹⁴. For the registration-evidence neighbour, see why an NMPA-registered laser fiber without a Medison CE claim does not inherit EU REP.

The incoming decision: If an incoming inspection team found an EU REP or EC REP symbol on this laser-fiber packaging, that artwork would be the wrong file. Without a Medison CE claim for the SKU, the pouch would be signalling an MDR Article 11 authorised representative for a device that is not being placed on the Union market as a CE-marked Medison product. The negative rule is operational, not analogical: an NMPA-only device without a CE mark should not carry EC REP or EU REP.

Capital Equipment Scope Boundary: The NOVACURE Diode Laser System:

VEMERIX marketing and clinical materials describe complete vascular procedure solutions that pair Medison's disposable 1470 nm laser fibers with a partner-supplied diode laser console (the NOVACURE platform). In regulatory registers and technical dossiers, the NOVACURE console carries an independent CE mark held by its external manufacturer. Procurement teams must observe strict entity boundaries: the partner's CE mark and European authorised representative cover the capital generator only. That CE status cannot be transferred, extended, or imputed to Medison's consumable laser fiber. Each device SKU must stand on its own independent regulatory documentation.

Distributor incoming-label checklist, red flags, and the pack to request before accepting the lot

To replace confusion with a deterministic standard operating procedure, distributor quality teams, OEM incoming-inspection departments, and hospital receiving docks should execute the following seven-step verification protocol for any incoming shipment of sterile single-use medical devices.

1. Step 1 — Confirm Exact SKU CE Scope: Retrieve the supplier's CE certificate and confirm that the exact product code, catalog number, and model designation printed on the carton appear within the scope of the notified body certificate. Verify certificate authenticity and NANDO status without assuming notified-body review is required for the editorial symbol update ³, ⁶.
2. Step 2 — Verify Legal Manufacturer Identity: Inspect the primary pouch, unit box, and IFU to confirm that the legal manufacturer named beside the ISO 15223-1 Clause 5.1.1 factory symbol exactly matches the entity named on the CE certificate and Declaration of Conformity ², ⁶.
3. Step 3 — Inspect Clause 5.1.2 Authorised Representative Symbol: Verify that either EC REP or EU REP appears enclosed within the standard rectangular symbol border. Confirm that the symbol is immediately adjacent to the full legal name, registered trade name, and physical address of the European authorised representative ¹, ³.
4. Step 4 — Cross-Check Across Packaging Tiers: Confirm that the authorised representative's name and physical address are 100% identical between the primary sterile pouch, the secondary carton, and the printed IFU. Staggered symbol presentation (e.g. EC REP on pouch, EU REP on box) is fully conforming; conflicting entity names or addresses represent a critical defect ³.
5. Step 5 — Audit Declaration of Conformity Standards Citation: Review the manufacturer's signed EU Declaration of Conformity. The DoC may cite either EN ISO 15223-1:2021 or EN ISO 15223-1:2021/A1:2025. Both citations confer full statutory presumption of conformity until 15 June 2031 (MDR) or 17 June 2031 (IVDR) ⁴, ⁵.
6. Step 6 — Inspect Over-Labels (Where Present): If an over-label has been applied to update contact details or transition to EU REP, verify that it adheres securely, does not obscure the UDI barcode, lot number, or expiration date, and does not compromise the sterile barrier seal ³.
7. Step 7 — US Shipments Symbols Glossary Check: If the shipment is routed to or through the United States, confirm that the package insert or labeling bears an identified Symbols Glossary conforming to 21 CFR 801.15 explaining all standalone symbols ⁹.

The table below details the specific operational action required for every observable incoming artwork scenario:

Before issuing a purchase order or accepting a container, distributors should request the following standardized Labeling Due Diligence Pack from the manufacturer:

• Artwork Proofs: Approved engineering 1:1 artwork drawings for the primary sterile pouch, folding carton, shipper box, and printed IFU.
• Article 11 Mandate: A fully executed, unexpired Authorised Representative Mandate agreement signed by the legal manufacturer and the EU authorised representative.
• EU Declaration of Conformity: Current signed DoC referencing Regulation (EU) 2017/745 and listing the applicable harmonised standards.
• Symbols Glossary: A controlled document detailing every symbol utilized across the device packaging, cross-referenced to ISO 15223-1 and 21 CFR 801.15.
• Art. 60 CFS Context: When distributing outside the EU against European export documentation, see our guide on why a Certificate of Free Sale naming an EC REP does not prove the current pouch symbol.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. For international distributors, OEM/ODM private-label partners and procurement committees, the useful next step on this topic is a current artwork and authorised-representative-mandate conversation—not a slogan that every SKU already prints EU REP, or that VEMERIX sells authorised-representative services.

In managing our international product packaging, VEMERIX adheres to clear, verified boundaries:

• CE-marked surgical line (circumcision platforms): For the CE-marked VEMERIX Circumcision Device, a pouch that still prints EC REP during the coexistence window is not automatically nonconforming under Decision (EU) 2026/1231. VEMERIX can discuss current pouch, carton and IFU artwork, the matching Article 11 mandate, and the Declaration of Conformity that names EN ISO 15223-1:2021 with or without A1:2025. This page does not publish that artwork or name the authorised representative.
• NMPA-registered laser consumables: For the Disposable Medical Laser Fiber, the public product page records NMPA Class II registration without a Medison CE mark. An EU authorised-representative symbol does not belong on that SKU by analogy ¹⁴.
• No capital-system imputation: Laser fibers may be used with the partner-supplied NOVACURE diode laser source in clinical workflows. The partner console’s CE flag is not a Medison-manufactured capital-system claim and does not confer EU REP on the fiber.
• No standalone AR agency: VEMERIX does not sell third-party EU authorised-representative services. The conversion path on this topic is a request for the current labelling pack on CE-marked lines, via quality or contact.

Distributors, hospital clinical-engineering leads, and OEM buyers seeking specimen artwork files, technical dossiers, or Declaration of Conformity packs for our CE-marked urology lines can contact our regulatory affairs team directly via our quality portal or reach out through our international contact desk.

Frequently asked questions

Is EC REP still legal on an EU medical-device label in 2026?
Yes. Commission Implementing Decision (EU) 2026/1231 for the MDR and Decision (EU) 2026/1313 for the IVDR maintain the presumption of conformity for the unamended standard until mid-June 2031. During this five-year transitional period, EC REP remains entirely legal, conforming, and acceptable across all EU Member States.

Do I need notified-body approval to change EC REP to EU REP?
No. MDCG 2021-5 Rev. 1 Appendix confirms that changing the letters from 'EC' to 'EU' within the Clause 5.1.2 symbol is a purely editorial modification. It does not affect device safety, performance, or the legal mandate, and manufacturers do not require prior notified-body review, approval, or certificate supplements.

When does EC REP stop conferring a presumption of conformity under the MDR and under the IVDR?
Under MDR Implementing Decision (EU) 2026/1231 Article 2, the deletion of the unamended standard applies from 15 June 2031. Under IVDR Implementing Decision (EU) 2026/1313 Article 2, deletion applies from 17 June 2031. After those respective dates, only the amended standard (using EU REP) confers the harmonised standard presumption of conformity.

Does FDA require EU REP on a device shipped to the United States?
No. United States FDA medical device regulations do not require an authorised representative symbol. Under 21 CFR Part 801, labels require the manufacturer, packer, or distributor name and place of business. If an EU REP or EC REP symbol is printed on global multi-market packaging, it is considered supplementary export information, but if standalone symbols are used without adjacent English text, 21 CFR 801.15 mandates an accompanying Symbols Glossary.

Can I print both EC REP and EU REP during the transition?
Yes. MDCG 2021-5 Rev. 1 Appendix explicitly permits staggered implementation across packaging levels. For example, a manufacturer may use EC REP on the primary sterile pouch while displaying EU REP on the folding carton or IFU, provided that the legal identity and address of the authorised representative remain completely identical across all materials.

Does an NMPA-only device need an EU authorised-representative symbol?
No. An NMPA-registered device commercialized outside the European Union without an active European CE certificate must never carry an EC REP or EU REP symbol. Affixing an authorised representative symbol to a non-CE device falsely communicates European regulatory oversight and constitutes an immediate regulatory violation.

Is EU REP a different person from the EC REP named in the existing mandate?
No. The symbol change from EC REP to EU REP is an editorial update to treaty terminology. It does not alter the underlying legal entity, company registration, mandate agreement, or statutory responsibilities of the authorised representative appointed under MDR Article 11.

Does VEMERIX already print EU REP on every SKU?
No. Packaging change control follows the statutory clocks rather than a claim that every SKU has already switched. For the CE-marked circumcision ring, EC REP remains a conforming clause 5.1.2 symbol during coexistence under Decision 2026/1231; later reprints may move to EU REP without treating that as an emergency recall. NMPA-only products, including the single-use laser fiber, should not carry a European authorised-representative symbol. Request the current artwork rather than inferring it from this article.